An observational study in Fibromyalgia, sponsored by Mardin Artuklu University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Mardin Artuklu University · Observational
This study aims to investigate the relationship between everyday cognitive failures and medication adherence in adults with fibromyalgia.
Fibromyalgia is a chronic condition associated with widespread pain, fatigue, and cognitive difficulties such as forgetfulness and problems with attention. These difficulties may affect patients' ability to take prescribed medications regularly, but their relationship with medication adherence remains unclear.
This single-center, observational, cross-sectional study will include 70 adults aged 18-65 years diagnosed with fibromyalgia who regularly take at least one medication for the condition.
Everyday cognitive failures will be assessed using the Cognitive Failures Questionnaire (CFQ), and medication adherence will be assessed using the five-item Medication Adherence Report Scale (MARS-5). Anxiety and depressive symptoms will be evaluated using the Hospital Anxiety and Depression Scale (HADS). Information on pain severity, medications, and daily medication-taking frequency will also be collected.
The study will examine whether greater cognitive failures are associated with lower medication adherence and whether this relationship remains after accounting for anxiety, depressive symptoms, number of regularly used medications, and daily medication-taking frequency.
All assessments will be completed during a single visit lasting approximately 12-15 minutes. No experimental treatments, additional laboratory tests, or invasive procedures will be performed.
Cognitive difficulties are frequently reported by individuals with fibromyalgia and may involve attention, memory, and everyday cognitive functioning. Although cognitive impairment and medication adherence have been investigated separately in fibromyalgia, the relationship between everyday cognitive failures and adherence to prescribed medication remains insufficiently understood.
The primary objective of this study is to evaluate the association between everyday cognitive failures, measured by the Cognitive Failures Questionnaire (CFQ), and medication adherence, measured by the five-item Medication Adherence Report Scale (MARS-5).
The MARS-5 total score will serve as the primary outcome variable, while the CFQ total score will be the main explanatory variable. Higher MARS-5 scores indicate better medication adherence, whereas higher CFQ scores indicate more frequent everyday cognitive failures. For participants using multiple medications for fibromyalgia, adherence will be assessed for the medication used regularly for the longest duration.
The relationship between CFQ and MARS-5 total scores will be examined using Pearson or Spearman correlation analysis, depending on the distribution of the data.
A multivariable linear regression model will additionally be used to assess whether cognitive failures are independently associated with medication adherence after adjustment for anxiety symptoms, depressive symptoms, the number of regularly used medications, and daily medication-taking frequency.
Exploratory analyses will investigate the associations of age, sex, educational level, duration of fibromyalgia, and pain severity with CFQ and MARS-5 scores.
The study will be conducted at the Physical Medicine and Rehabilitation Outpatient Clinic of Mardin Training and Research Hospital, Türkiye. Participants will complete all assessments during a single visit without any additional medical intervention.
As this is a cross-sectional study, the findings will be interpreted as associations and will not establish causal relationships.
1,243 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.
This study's planned enrollment of 70 is below the median of 100 across 279 observational studies indexed under Fibromyalgia.
Browse Fibromyalgia studies →Mardin Artuklu University is the lead sponsor of 34 studies on the registry; 15 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population will consist of 70 adults aged 18-65 years diagnosed with fibromyalgia according to the 2016 ACR criteria and regularly taking at least one medication for fibromyalgia. Participants will be recruited from the Physical Medicine and Rehabilitation Outpatient Clinic of Mardin Training and Research Hospital, Türkiye. Eligible patients who provide written informed consent will undergo a single-visit assessment of everyday cognitive failures, medication adherence, anxiety and depressive symptoms, pain severity, and medication use.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults aged 18-65 years diagnosed with fibromyalgia according to the 2016 American College of Rheumatology (ACR) criteria and regularly taking at least one medication for fibromyalgia. Participants will undergo a single-visit assessment using the Cognitive Failures Questionnaire (CFQ), Medication Adherence Report Scale (MARS-5), and Hospital Anxiety and Depression Scale (HADS). Demographic characteristics, pain severity, and medication use will also be recorded. No experimental interventions or additional medical procedures will be performed.
Medication Adherence Assessed by MARS-5 in Relation to Pain Severity
Medication adherence will be measured using the five-item Medication Adherence Report Scale (MARS-5). Total scores range from 5 to 25, with higher scores indicating better medication adherence. The association between MARS-5 total scores and pain severity, assessed using the Numeric Rating Scale (NRS; 0-10), will be examined as an exploratory analysis. MARS-5 will be the outcome variable, and pain severity will be the explanatory variable.
Time frame: Baseline
Everyday Cognitive Failures Assessed by the Cognitive Failures Questionnaire (CFQ)
Everyday cognitive failures will be assessed using the 25-item Cognitive Failures Questionnaire (CFQ). Each item is scored from 0 to 3, yielding a total score ranging from 0 to 75. Higher scores indicate more frequent everyday cognitive failures, whereas lower scores indicate fewer cognitive failures.
Time frame: Baseline
Anxiety Symptoms Assessed by the Hospital Anxiety and Depression Scale (HADS-A)
Anxiety symptoms will be assessed using the seven-item anxiety subscale of the Hospital Anxiety and Depression Scale (HADS-A). Each item is scored from 0 to 3, yielding a total score ranging from 0 to 21. Higher scores indicate more severe anxiety symptoms, whereas lower scores indicate fewer anxiety symptoms.
Time frame: Baseline
Pain Severity Assessed by the Numeric Rating Scale (NRS)
Average fibromyalgia pain severity during the preceding week will be assessed using the Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate greater pain severity, whereas lower scores indicate less pain.
Time frame: Baseline
Plan to share: No
Start is estimated for Dec 2026; primary completion for Nov 2027, 11 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mardin Artuklu University